xeljanz tofacitinib 11mg, Buy Tofacitinib 11 mg Online, Buy Xeljanz 11 mg online, Buy Tofacinix 11 mg online.

xeljanz tofacitinib 11mg, Tofacitinib, sold under the brand Xeljanz / Tofacinix, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacinix is the alternative of Xeljanz.

Indications

Rheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

Therapeutic Class

Immunosuppressant

Pharmacology

Rheumatoid arthritis is an autoimmune disease characterized by a dysregulation of pro-inflammatory cytokines including IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Cytokines signalling results in tissue inflammation.

Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs.

The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Xeljanz works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response.

Dosage & Administration

Rheumatoid Arthritis: Xeljanz 5 mg twice daily or Xeljanz 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Xeljanz 5 mg once daily.

Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Xeljanz 11 mg once daily.  Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Xeljanz 5 mg once daily.

Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.

Interaction

Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)

Recommended dose is Xeljanz 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)

Recommended dose is Xeljanz 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.

Side Effects

The most reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with Tofacitinib monotherapy or in combination with DMARDs) were upper respiratory tract infections.

Pregnancy & Lactation

Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether Xeljanz is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from

Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, considering the importance of the drug for the mother

Precautions & Warnings

Serious Infections: Avoid use of Xeljanz during an active serious infection, including localized infections.

Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.

Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.

Immunizations: Live vaccines: Avoid use with Xeljanz.

Do not initiate Xeljanz if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.

Use in Special Populations

Pediatric Use: The safety and effectiveness of Xeljanz in pediatric patients have not been established.

Geriatric Use: The frequency of serious infection among Xeljanz-treated subjects 65 years of age and older was higher than among those under the age of 65.

As there is a higher incidence of infections in the elderly population in general, caution should be used when treating the elderly.

Moderate and severe renal impairment or moderate hepatic impairment: half the total daily dosage recommended for patients with normal renal and hepatic function.

Storage Conditions

Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.